ArticleJournal of translational medicine2016
Combination of double negative T cells and anti-thymocyte serum reverses type 1 diabetes in NOD mice.
Article in Journal of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Adenosine signaling promotes double-negative T-cell anticancer responses in conditions of CD8 T-cell lymphopenia.Blood immunology & cellular therapy · 2026Article
- (TCRαβCells · 2025Review
- Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice.BMC medicine · 2025Article
- Characterization and effective expansion of CD4Molecular therapy. Methods & clinical development · 2025Article
- Purinergic signaling by TCRαβScience bulletin · 2025Article
- Association of TCRαβFrontiers in immunology · 2025Article
- Article
- CD3Frontiers in immunology · 2025Review
- Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.TouchREVIEWS in endocrinology · 2023Review
- Pancreatic draining lymph nodes (PLNs) serve as a pathogenic hub contributing to the development of type 1 diabetes.Cell & bioscience · 2023Review
- Review
- Evidence of genetic epistasis in autoimmune diabetes susceptibility revealed by mouse congenic sublines.Immunogenetics · 2021Article
- CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis.Nature communications · 2021Article
- DNT Cell-based Immunotherapy: Progress and Applications.Journal of Cancer · 2020Review
- Double negative T cells mediate Lag3-dependent antigen-specific protection in allergic asthma.Nature communications · 2019Article
- Critical role of OX40 in the expansion and survival of CD4 T-cell-derived double-negative T cells.Cell death & disease · 2018Article
- Concomitant Disruption ofJournal of immunology (Baltimore, Md. : 1950) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDouble-negative (DN) T cells could delay the onset and the progression of autoimmune diabetes, yet they were less efficient on reversing autoimmune diabetes. The aim of this study was to investigate whether the combination of DN T cells and anti-thymocyte serum (ATS) could reverse new-onset diabetes in NOD mice.
methodsThe regulation of different subsets of T cells in vitro and in vivo by ATS and DN T cells were examined using flow cytometry. At the day of diabetes onset, ATS was administered on the same day and 2 days later, and DN T cells were transferred at day 7. The reversion of diabetes was assessed by monitoring blood glucose levels.
resultsThe efficacy of inhibition of DN T cells on CD8(+) T cells was lower than that on CD4(+) T cells both in vitro and in vivo. ATS resulted in a significant depletion of CD8(+) T cells, while DN T cells were less sensitive to ATS depletion. 80 % diabetic NOD mice achieved long term (6 months) reversion of diabetes by combined ATS and DN T cells treatment, compared to 16 % in ATS single treatment and none in DN T cell single treatment. DN T cells preferentially resided in spleen and pancreatic draining lymph nodes in ATS plus DN T cells treated NOD mice.
conclusionsDN T cells plus ATS therapy show promising reversion effects on diabetic NOD mice due to a shift of balance from a destructive T cell response to one that favors DN T cell regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.